ATOMO DIAGNOSTICS LIMITED — AGM Information 2021

Oct 27, 2021

Atomo Diagnostics Limited ACN 142 925 684

701 – 703 Parramatta Road Leichhardt NSW 2040 Australia

==> picture [264 x 257] intentionally omitted <==

==> picture [296 x 258] intentionally omitted <==

ANNUAL GENERAL MEETING Thursday 28 October 2021 Managing Director’s Presentation

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

DISCLAIMER

This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on information available as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. Reliance should not be placed on the information or opinions contained in this presentation. An investor must not act on the basis of any matter contained in this presentation but should make its own assessment of Atomo as part of its own investigations.

This presentation has been provided for general information purposes only. It does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Atomo, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs.

Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any other person, accepts any responsibility or liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. This disclaimer also extends to all and any information and opinions contained in, and any omissions from, any other written or oral

communications transmitted or otherwise made available to the recipient in connection with the opportunity outlined in this presentation and no representation or warranty is made in respect of such information.

The information presented in this presentation is subject to change without notice and Atomo does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The cover image is illustrative only.

This presentation may contain certain forward looking statements that are based on Atomo’s beliefs, assumptions and expectations and on information currently available to Atomo management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Atomo to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding present and future business strategies and the business, economic and competitive environment in which they operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation).

==> picture [33 x 32] intentionally omitted <==

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

ATOMO’S VISION

Re-imagining Diagnostics

VISION

Empowering people to enjoy healthier, more informed lives through fast, accurate point of care testing.

MISSION

Re-imagining diagnostics by putting the user point of care experience at the centre of everything we do. Atomo's mission is to ensure equitable and affordable access to accurate diagnoses ensuring a seamless pathway to treatment.

VALUES

==> picture [28 x 27] intentionally omitted <==

Impact - Commercialising products that matter to our users Innovation - Fostering creative thinking and solutions

==> picture [26 x 23] intentionally omitted <==

==> picture [28 x 25] intentionally omitted <==

Integrity - Ensuring honesty and fairness in all that we do Collaboration - Working as one global team Excellence - Being recognised as experts in the field

==> picture [32 x 30] intentionally omitted <==

==> picture [27 x 24] intentionally omitted <==

==> picture [33 x 32] intentionally omitted <==

3

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

CORPORATE PROFILE

Key financial details
ASX code	AT1
Share price (27/10/21)	$0.305
Shares on issue	568.6m
Options on issue	23.7m
Market cap*	$173m
Current cash (30/09/21)	$15.2m

*Undiluted

Board Member	Position
John Keith	Non-Executive Chairman
John Kelly	Founder and Managing Director
Dr Curt LaBelle	Non-Executive Director
Connie Carnabuci	Non-Executive Director
Dr Paul Kasian	Non-Executive Director
Deborah Neff	Non-Executive Director*

Share price performance

==> picture [364 x 201] intentionally omitted <==

Major Shareholders	% (undiluted)
Dalraida Holdings Pty Ltd / John Kelly	13.1%
Global Health Investment Fund I, LLC	11.4%
Ellerston Capital Limited	7.31%
Walker Group Holdings Pty Ltd	6.70%

As per substantial shareholder notices

==> picture [33 x 32] intentionally omitted <==

4

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

*Appointed 15 September 2021

KEY HIGHLIGHTS - FY21

• Atomo COVID-19 rapid tests – Added by the TGA to the ARTG in H1 FY21 for supply in Australia. Tests launched in Q2 & Q3 FY21. Circa. 50k, primarily antibody test units sold in 2H FY21.

• Regulatory Approval – Atomo devices have now achieved broad regulatory approvals including FDA, CE Mark, TGA & WHO prequalification (Atomo and Customer Finished tests)

• HIV - Global health agreement signed between Mylan (Viatris)/Atomo and Unitaid in Q4 FY21 covering more than 135 countries. Initial orders commenced

• OEM/Co-development business – Ongoing technical and commercial engagement progressing with several leading multinational diagnostics companies seeking access to Atomo’s rapid blood test platforms and proprietary functionality for non-blood test applications

• US market entry – Business development/commercial resourcing and local entity infrastructure currently being established to support expanded engagement in the US

• New product development - Atomo commences development of first non-blood rapid test platform in Q4 FY21

• Financials – Sales growth of 25%, cash receipts of ~$8m and cash at bank of $18m at 30/6/21

==> picture [285 x 363] intentionally omitted <==

==> picture [33 x 32] intentionally omitted <==

5

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

FY21 SUMMARY FINANCIALS

AUD	FY21	FY20	Variance
Sales ($m)	6.72	5.37	25%
Gross Margin ($m)	3.42	3.19	7%
GP margin (%)	51%	60%
EBITDA ($m)	(4.79)	(2.38)	(101%)

==> picture [423 x 235] intentionally omitted <==

==> picture [394 x 240] intentionally omitted <==

==> picture [179 x 13] intentionally omitted <==

----- Start of picture text -----

Sales Revenue Split by Product
----- End of picture text -----

==> picture [217 x 122] intentionally omitted <==

----- Start of picture text -----

30%
54%
16%
COVID-19 HIV Other OEM
----- End of picture text -----

==> picture [33 x 32] intentionally omitted <==

6

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

STRATEGIC FOCUS

Capabilities

Innovation, Co-development & Commercialisation

(device design, regulatory, usability, e-health, IP)

Markets

• Infectious Rapid Test Consumer Health

• Diseases Tests Devices & Wellness

• (HIV, COVID, Others) (devices, components) (entering new markets) Channels

• • • • Channel partners Atomo in-house supply Telehealth/Home health

• • • • Direct to consumers OEM device partners Online wellness

• • • • Co-commercialisation partners Co-development/licensing Pharmacy/Retail

==> picture [33 x 32] intentionally omitted <==

7

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

ATOMO’S CORE CAPABILITIES

The intersection between Medical Devices & User-friendly Diagnostics

==> picture [626 x 26] intentionally omitted <==

==> picture [112 x 28] intentionally omitted <==

----- Start of picture text -----

Less IP Intensive
More sales focused
----- End of picture text -----

IP Intensive

==> picture [81 x 81] intentionally omitted <==

==> picture [126 x 87] intentionally omitted <==

==> picture [80 x 79] intentionally omitted <==

==> picture [74 x 71] intentionally omitted <==

==> picture [100 x 41] intentionally omitted <==

Finished Product

Devices

Customer Delivery

==> picture [81 x 11] intentionally omitted <==

----- Start of picture text -----

Atomo DNA
----- End of picture text -----

Core Functionality

• Point-of-Care Self Testing • Blood collection • Galileo

  • Digital delivery

• HIV

• Saliva & swab collection • Pascal

  • Subscription models

• COVID

• Design and engineering

• Buffer delivery

• Elion

• Other

• White label brands

• Patent generation

• Interlocks • Da Vinci

• Prototype and trial

• Manufacturing machinery • and processes devices

  • Non-Blood

• Co-development

• Regulatory processes

• IFU’s

• User centric design

• Digital, App

==> picture [33 x 32] intentionally omitted <==

8

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRODUCTS AND CUSTOMERS

	P R O D U C T S	C U S T O M E R S / C H A N N E L S
Infectious	HIV-Self Test and Professional	Iyeza, Owen Mumford (UK/EU) Mylan/Viatris (LMIC), Australia - Distributors
Diseases Tests
(HIV, COVID, Others)	COVID-Antigen and Antibody	Atomo branded Antigen tests (Australia)
		OEM device for Antibody tests (NG and ABI)
Rapid Test Devices	Blood Devices-Galileo, Pascal, Elion (pending)	NG Bio, Lumos, ABI
(devices, components)	Non-Blood-Swab and Saliva
	(commenced)	In process
Consumer Health	HIV-Direct to consumer Australia	Expansion to pharmacy and removal of
& Wellness		restrictions on advertising and promotion
(entering new markets)	COVID-Emerging market in Australia	ST submission pending – eCommerce/ Pharmacy

==> picture [33 x 32] intentionally omitted <==

9

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

==> picture [33 x 32] intentionally omitted <==

ATOMO’S INFECTIOUS DISEASE BUSINESS

HIV

==> picture [21 x 35] intentionally omitted <==

==> picture [494 x 292] intentionally omitted <==

==> picture [26 x 26] intentionally omitted <==

==> picture [19 x 40] intentionally omitted <==

==> picture [61 x 60] intentionally omitted <==

COVID-19

COVID Antigen - Australia

Atomo has an opportunity to sell up to 20 million antigen tests during FY22 & 23.

COVID OEM Devices

With extended market life, we see some opportunity to supply custom cassettes to leading COVID antigen home tests

Neutralising Antibody

There is some prospect of neutralising antibody testing becoming a sizeable market channel

10

HIVST = HIV Self-test

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

CO-DEVELOPMENT BUSINESS

==> picture [52 x 53] intentionally omitted <==

GOAL: To become the leading provider of integrated Rapid test devices by leveraging Atomo’s capabilities, IP and know-how by offering Co-Development partners access to Atomo’s platforms and proprietary components

Accelerate roll-out of current technologies with existing approvals to existing markets (Europe, Australia) and new markets (US) with potential for partners to upgrade existing products to an Atomo platform

==> picture [34 x 55] intentionally omitted <==

Leverage existing platforms

Atomo’s development & usability expertise, portfolio of patent protected technologies and proprietary knowhow to enhance a Partner’s portfolio of assets, products and sample types

==> picture [34 x 56] intentionally omitted <==

Development beyond blood

Custom Work with partners for bespoke solutions that leverage Development Atomo’s existing technology, that allow for cost-sharing new developments, and create locked in customer relationships through supply, licensing and royalties

==> picture [211 x 47] intentionally omitted <==

Elion: developed but not yet commercialised

Swab and saliva rapid test concepts in development

Technical discussions in process

==> picture [33 x 32] intentionally omitted <==

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

11

TELEHEALTH: OPENING NEW MARKETS FOR ATOMO

• COVID-19 has accelerated personalised, predictive and preventive medicine programs

• Consumer adoption and growth in Telehealth, POCT, OTC and at-home self-testing markets

• Telehealth consultations 38x higher than before the pandemic*

• Historical uncertainty from health care providers towards self-testing/at-home testing has been reduced

• Precedents have been set with regulatory authorities to approve self-testing technologies

• Usability, simplicity and accuracy are critical for diagnostics use in these settings

==> picture [657 x 231] intentionally omitted <==

==> picture [33 x 32] intentionally omitted <==

• [Source: McKinsey & Co, Telehealth: A quarter-trillion-dollar post-COVID-19 reality? July 2021]

12

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)

PRIORITIES FOR FY22*

==> picture [63 x 139] intentionally omitted <==

Capitalising on local COVID-19 opportunities, including launch of a self-test product (subject to TGA approval), and increasing resources to support growing demand across public health and private sector channels

Progressing strategic partnership opportunities with large diagnostics companies looking to improve the usability and marketability of their existing point-of-care testing products, as they seek to enter the rapidly growing home-based telehealth market

==> picture [62 x 216] intentionally omitted <==

Growing Atomo’s HIV business through the support of key partners rolling out Atomo’s HIV products globally, developing new markets and expanding Atomo’s domestic sales channels given recent supportive TGA changes enabling pharmacy sales and product advertising

Ongoing development of non-blood rapid test solutions, including for swab and saliva rapid testing and so significantly expanding Atomo’s addressable market in point-of-care testing (POCT)

Establishing Atomo’s US business and upgrading the Company’s commercial and business resources, capabilities and infrastructure

==> picture [33 x 32] intentionally omitted <==

*The priorities above reflect the Company’s intentions in FY22 only. They have been provided as a general guide and should not be relied upon as an indication or guarantee of future performance. There is no guarantee that these priorities will eventuate

ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)